128 related articles for article (PubMed ID: 3096090)
21. Effects of contraceptive pills and intrauterine devices on urinary bladder.
Zahran MM; Osman MI; Kamel M; Fayad M; Mooro H; Youssef AF
Urology; 1976 Dec; 8(6):567-74. PubMed ID: 793141
[TBL] [Abstract][Full Text] [Related]
22. Reversible contraception for the woman over 35 years of age.
Archer DF
Curr Opin Obstet Gynecol; 1992 Dec; 4(6):891-6. PubMed ID: 1450355
[TBL] [Abstract][Full Text] [Related]
23. ICMR task force study on hormonal contraception. Transfer of levonorgestrel (LNG) administered through different drug delivery systems from the maternal circulation into the newborn infant's circulation via breast milk.
Shikary ZK; Betrabet SS; Patel ZM; Patel S; Joshi JV; Toddywala VS; Toddywala SP; Patel DM; Jhaveri K; Saxena BN
Contraception; 1987 May; 35(5):477-86. PubMed ID: 3113823
[TBL] [Abstract][Full Text] [Related]
24. Endometrial lymphomyeloid cells in abnormal uterine bleeding due to levonorgestrel (Norplant).
Clark DA; Wang S; Rogers P; Vince G; Affandi B
Hum Reprod; 1996 Jul; 11(7):1438-44. PubMed ID: 8671483
[TBL] [Abstract][Full Text] [Related]
25. NORPLANT implants and the TCu 200 IUD: a comparative study in Ecuador.
Marangoni P; Cartagena S; Alvarado J; Díaz J; Faúndes A
Stud Fam Plann; 1983; 14(6-7):177-80. PubMed ID: 6414119
[No Abstract] [Full Text] [Related]
26. Contraception with subdermal implants releasing levonorgestrel. A clinical and pharmacological study.
Olsson SE
Acta Obstet Gynecol Scand Suppl; 1987; 142():1-45. PubMed ID: 3116821
[TBL] [Abstract][Full Text] [Related]
27. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM
Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
[TBL] [Abstract][Full Text] [Related]
28. A new delivery system for contraceptive steroids.
Segal S
Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 2):1090-2. PubMed ID: 3118719
[TBL] [Abstract][Full Text] [Related]
29. Continuation rates of long-acting methods of contraception. A comparative study of Norplant implants and intrauterine devices.
Fleming D; Davie J; Glasier A
Contraception; 1998 Jan; 57(1):19-21. PubMed ID: 9554246
[TBL] [Abstract][Full Text] [Related]
30. Levonorgestrel plasma levels during continuous administration with different models of subdermal implants.
Alvarez F; Brache V; Faundes A; Johansson ED; Odlind V; Nash H
Contraception; 1983 Feb; 27(2):123-30. PubMed ID: 6406138
[TBL] [Abstract][Full Text] [Related]
31. New concepts in contraception: Norplant subdermal implant.
Lynn MM; Holdcroft C
Nurse Pract; 1992 Mar; 17(3):85-9. PubMed ID: 1565306
[TBL] [Abstract][Full Text] [Related]
32. Ultrasonic visualization of NORPLANT subdermal contraceptive devices.
Thomsen RJ; Pasquale S; Nosher J
Int J Gynaecol Obstet; 1985 Jun; 23(3):223-7. PubMed ID: 2865186
[TBL] [Abstract][Full Text] [Related]
33. The effects of Implanon on lipid metabolism in comparison with Norplant.
Suherman SK; Affandi B; Korver T
Contraception; 1999 Nov; 60(5):281-7. PubMed ID: 10717780
[TBL] [Abstract][Full Text] [Related]
34. The NORPLANT contraceptive method: a report on three years of use.
Sivin I; Alvarez-Sanchez F; Diaz S; McDonald O; Holma P; Coutinho E; Robertson DN
Stud Fam Plann; 1982; 13(8-9):258-61. PubMed ID: 6814021
[No Abstract] [Full Text] [Related]
35. Cholesterol and HDL-cholesterol values in women during use of subdermal implants releasing levonorgestrel.
Holma P; Robertson DN
Contraception; 1985 Aug; 32(2):163-71. PubMed ID: 3935372
[TBL] [Abstract][Full Text] [Related]
36. Effect of subdermal levonorgestrel contraceptive implants, Norplant, on liver functions.
Shaaban MM; Elwan SI; el-Sharkawy MM; Farghaly AS
Contraception; 1984 Nov; 30(5):407-12. PubMed ID: 6440736
[TBL] [Abstract][Full Text] [Related]
37. Acceptability of an experimental intracervical device: results of a study controlling for selection bias.
Shain RN; Ratsula K; Toivonen J; Lähteenmäki P; Luukkainen T; Holden AE; Rosenthal M
Contraception; 1989 Jan; 39(1):73-84. PubMed ID: 2491982
[TBL] [Abstract][Full Text] [Related]
38. Hormonal treatment for bleeding irregularities in Norplant implant users.
Alvarez-Sanchez F; Brache V; Thevenin F; Cochon L; Faundes A
Am J Obstet Gynecol; 1996 Mar; 174(3):919-22. PubMed ID: 8633669
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of enlarged ovarian follicles among users of levonorgestrel subdermal contraceptive implants (Norplant).
Alvarez-Sanchez F; Brache V; de Oca VM; Cochon L; Faúndes A
Am J Obstet Gynecol; 2000 Mar; 182(3):535-9. PubMed ID: 10739504
[TBL] [Abstract][Full Text] [Related]
40. Norplant contraceptive subdermal implants: one year experience in Singapore.
Singh K; Viegas OA; Ratnam SS
Contraception; 1988 May; 37(5):457-69. PubMed ID: 3136971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
